 |
|
|
| |
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) shows high efficacy in clinical study participants infected with HIV-1 subtype F
|
| |
| |
Glasgow October 5-8, 2020, Glasgow, UK
Reported by Jules Levin
Rima K. Acosta*, Kristen Andreatta, Michelle L. D'Antoni, Sean E. Collins, Hal Martin, and Kirsten L. White
Gilead Sciences, Inc., Foster City, California, USA
|
| |
|
|
|
|
|
